Annexon’s leadership has an extensive and successful track-record of discovering, developing and commercializing breakthrough therapies for debilitating disease. Using a closely integrated approach, they are bound by their passion and commitment to translate Annexon’s platform science into break-through therapeutics for patients and their families impacted by complement mediated neurodegenerative diseases (CMND).
Douglas Love, Esq
President & Chief Executive Officer
Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in May 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals where he led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales. He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion in addition to milestones and royalties. Mr. Love is a corporate attorney by training, and prior to joining Elan served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.
Eduardo Dunayevich, MD
Executive VP & Chief Medical Officer
Dr Dunayevich joined Annexon Biosciences as Chief Medical Officer in October 2107. Dr Dunayevich was previously Vice President and Global Product Lead for Takeda Pharmaceuticals, an Executive Director of Clinical Development for both Takeda and Amgen, Chief Medical Officer at Orexigen Therapeutics and a Medical Advisor at Eli Lilly and Co. During his industry career spanning over 15 years, he has led numerous development programs in neuropsychiatric indications across all stages of development. As a CMO at Orexigen, he was responsible for all clinical development programs and the NDA of Contrave©, a now marketed anti-obesity drug. Prior to joining the industry, Dr Dunayevich was clinical faculty at the University of Cincinnati, where he received his psychiatry board certification training and was involved in clinical care and research. Dr Dunayevich attended medical school at the University of Buenos Aires, Argentina, where he obtained his medical degree.
Ted Yednock, PhD
Chief Scientific Officer
Dr. Yednock joined Annexon Biosciences as Chief Scientific Officer in November 2013. Dr. Yednock was previously Chief Scientific Officer for Prothena Corporation, Head of Research for Elan Pharmaceuticals and a Scientist at Athena Neurosciences. While at Athena, he was the scientific inventor of Tysabri®, a blockbuster monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock earned his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California San Francisco.
Susan Kramer, DrPH
VP, Product development
Dr. Kramer joined Annexon Biosciences as Vice President, Product Development in July 2015. A seasoned biopharmaceutical executive with more than 25 years of industry experience and a strong focus on product development and alliance management, Dr. Kramer directed program management activities at KaloBios for three development-stage antibodies, and led the global program management for the XOMA-Servier development candidate gevokizumab. Prior to joining XOMA, Dr. Kramer served as Vice President of Development at Anesiva, where she led the development of Adlea™, a non-opioid analgesic, as well as managed non-clinical and bioanalytical development departments. In 2003, Dr. Kramer co-founded Corthera, Inc., and led the development of relaxin for use in orthodontics, congestive heart failure and preeclampsia.
Dr. Kramer started her career in the biotech industry at Genentech and spent 18 years working in a variety of laboratory and management roles of increasing responsibility, culminating in the position of Senior Director, Development Sciences Operations and Strategic Planning. She led several project teams including Actimmune® and Raptiva®, and managed alliances with Boehringer Ingelheim GmbH, Daiichi Seiyaku, Toray Industries and Fujisawa Pharmaceuticals. She is currently a member of the Scientific Advisory Board for Concentric Analgesics. Dr. Kramer holds Master and Doctor of Public Health degrees from the University of California, Berkeley, an M.A. in Education from Central Michigan University and a B.A. in Laboratory Science from the College of St. Scholastica.